Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
0 hedge funds and large institutions have $0 invested in Stemline Therapeutics, Inc. in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 94 closing their positions.
100% less funds holding
Funds holding: 94 → 0 (-94)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $194M → $0 (-$194M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 94
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$20.1M |
| 2 |
BlackRock
New York
|
-$18.1M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$16.2M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$14.9M |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$12.5M |
STML Hedge Fund Activity: Q2 2020 in Review
0 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q2 2020, worth a combined $0 — down 100% from $194M a quarter earlier.
Sellers outnumbered buyers: 94 funds closed out of STML and 0 opened new positions — a net loss of 94 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Eventide Asset Management, exiting entirely with an estimated $20.1M sold.
- 0 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q2 2020, down from 94 in Q1 2020.
- Funds reported $0 of Stemline Therapeutics, Inc. stock for Q2 2020, down 100% quarter-over-quarter.
- 0 funds opened new Stemline Therapeutics, Inc. positions in Q2 2020 and 94 closed out, a net change of -94 holders.
- The largest Stemline Therapeutics, Inc. seller in Q2 2020 was Eventide Asset Management, an estimated $20.1M sold.
Based on aggregated 13F filings for Q2 2020.